{"entity":{"id":"nct06014528","kind":"trial","name":"IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurren","aka":[],"tldr":"A phase 2 trial of IN10018, Pegylated liposomal doxorubicin in ovarian cancer, run by InxMed (Shanghai) Co., Ltd., now recruiting.","summary":"IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer is a phase 2 interventional study registered as NCT06014528 by InxMed (Shanghai) Co., Ltd., with 168 participants planned, started 2022-09-06 and due to reach its primary completion in 2026-12-24. Interventions recorded: IN10018, Placebo of IN10018, Pegylated Liposomal Doxorubicin. Conditions listed: Ovarian Cancer Recurrent. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06014528","url":"https://clinicaltrials.gov/study/NCT06014528"}],"tags":["ctgov-ingest"],"related":[],"cancers":["ovarian","platinum-resistant-ovarian-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy","topoisomerase-inhibitors"],"targets":[],"drugs":["in10018","pegylated-liposomal-doxorubicin"],"companies":["inxmed"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06014528","phase":"2","setting":"A Multicenter, Randomized, Double-Blind, Phase II Clinical Study of IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer","sponsor":"InxMed (Shanghai) Co., Ltd.","started":"2022-09-06","startedType":"actual","enrolled":168,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06014528/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"platinum-resistant-ovarian-cancer","kind":"cancer","name":"Platinum-resistant ovarian cancer","route":"/cancers/platinum-resistant-ovarian-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"in10018","kind":"drug","name":"IN10018","route":"/drugs/in10018/"},{"id":"pegylated-liposomal-doxorubicin","kind":"drug","name":"Pegylated liposomal doxorubicin","route":"/drugs/pegylated-liposomal-doxorubicin/"}],"company":[{"id":"inxmed","kind":"company","name":"InxMed","route":"/companies/inxmed/"}]}}